Last reviewed · How we verify
0.125% Bupivacaine
0.125% Bupivacaine, marketed by Wayne State University, is an established anesthetic in the healthcare sector. The key composition patent is set to expire in 2028, providing a clear timeline for potential generic competition. The primary risk lies in the loss of exclusivity post-2028, which could significantly impact revenue.
At a glance
| Generic name | 0.125% Bupivacaine |
|---|---|
| Also known as | Bupivacaine |
| Sponsor | Wayne State University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Parascapular Sub Iliocostalis Plane Block Versus Thoracic Paravertebral Plane Block for Traumatic Multiple Rib Fractures (NA)
- Epidural vs. Dural Puncture Epidural in Labor Analgesia (NA)
- Thoracic Epidural Analgesia With Bilateral Erector Spinae Plane Block in Radical Cystectomy Surgery (NA)
- Bilateral Two Levels Serratus Anterior Plane Block in Pediatric Cardiac Surgery With Median Sternotomy (NA)
- Comparison of Caudal and Quadratus Lumborum Blocks With Pain Monitoring in Children
- Intrapleural Bupivacaine Analgesia for Postoperative Pain Management After Minimally Invasive Video-Assisted Thoracoscopic Surgery: A Randomized Controlled Trial (PHASE4)
- Spinal Anesthesia For Enhanced Recovery After Liver Surgery (NA)
- Dural Puncture Epidural vs Standard Epidural Analgesia in Labor (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 0.125% Bupivacaine CI brief — competitive landscape report
- 0.125% Bupivacaine updates RSS · CI watch RSS
- Wayne State University portfolio CI